BMC Molecular and Cell Biology is a forward-thinking open-access journal published by BMC, specializing in the vital fields of molecular biology and cell biology. Since its inception in 2019, the journal has carved a niche for itself, ranking in the Q3 quartile in both Cell Biology and Molecular Biology categories as of 2023. With an ISSN of N/A and an E-ISSN of 2661-8850, the journal provides a platform for groundbreaking research, high-quality reviews, and innovative methodologies. Situated in the United Kingdom, BMC Molecular and Cell Biology promotes a diverse range of studies, addressing fundamental questions in biology that resonate with both experts and new researchers alike. The journal's commitment to open access ensures that valuable findings are readily available to the global scientific community, fostering collaboration and knowledge-sharing across disciplines. Researchers aiming to contribute to the field of cell and molecular biology will find this journal an indispensable resource for both publishing and staying informed on the latest advances.

BIOCELL is a distinguished peer-reviewed journal dedicated to the field of Cell Biology, published by TECH SCIENCE PRESS. Since its inception in 1995, the journal has been at the forefront of disseminating innovative research, with converged publication years extending from 1995 to 2013 and from 2015 to 2024. Although it currently holds a Q4 ranking in the Cell Biology category according to the 2023 category quartiles, BIOCELL aims to foster advancements by providing a platform for researchers, professionals, and students to share their findings in biochemistry, genetics, and molecular biology. The journal is available in both print (ISSN: 0327-9545) and digital formats (E-ISSN: 1667-5746) and seeks to attract contributions that enhance scholarly dialogue and understandings of cellular mechanisms and innovations. With a commitment to quality research and critical discourse, BIOCELL plays an important role in nurturing the scientific community within Argentina and beyond, offering vital insights that contribute to the advancement of the life sciences.

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

Frontiers in Bioscience-Landmark is a prestigious journal published by IMR PRESS that focuses on a diverse array of topics within the fields of biochemistry, genetics, molecular biology, immunology, and microbiology. With the ISSN 2768-6701 and E-ISSN 2768-6698, this journal has carved a significant niche since its inception in 1996, making its mark in contributions to the scientific community all the way through to 2024. Having achieved a respectable Q2 cohort rank in multiple categories, including biochemistry and immunology, it stands out for its impactful research, evidenced by its current Scopus rankings which highlight it as a vital resource for ongoing studies and advancements in the biosciences. Despite not being open access, the journal ensures that readers have access to high-quality research articles that are peer-reviewed and designed to foster academic discourse. The importance of Frontiers in Bioscience-Landmark lies in its commitment to disseminating innovative findings that can significantly enhance our understanding of biological sciences, making it an essential read for researchers, professionals, and students alike.

Acta Naturae is a peer-reviewed scientific journal published by the Russian Federation Agency for Science & Innovation, focusing on the dynamic fields of Biochemistry, Biotechnology, Molecular Biology, and Molecular Medicine. Launched in 2013, the journal has established a solid reputation in the academic community, with its articles contributing to essential advancements and discussions within these disciplines. By 2023, it has achieved notable rankings—including Q2 status in Biotechnology and Q3 in Biochemistry, Molecular Biology, and Molecular Medicine—indicating its growing influence and relevance in the scientific literature. While currently operating under a non-open access model, Acta Naturae invites researchers, professionals, and students to engage with its comprehensive research reports and reviews that span the breadth of molecular life sciences. With the aim of facilitating scientific dialogue and innovation, this journal serves as a key resource for those seeking to stay at the forefront of molecular research.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

FASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.

Cell Journal is a leading interdisciplinary publication in the fields of Cell Biology, Developmental Biology, Molecular Biology, and Reproductive Medicine, published by ROYAN INST since its inception as an open-access journal in 2007. With an ISSN of 2228-5806 for print and 2228-5814 for electronic editions, it provides a vital platform for researchers and professionals to disseminate innovative findings and insights that shape our understanding of cellular processes and reproductive sciences. The journal boasts an impressive Scopus ranking, achieving a Q3 position in both Molecular Biology and Reproductive Medicine, highlighting its significance in the academic community. Situated in Tehran, Iran, Cell Journal encourages global collaboration through its accessible content, making cutting-edge research available to a diverse audience. As it converges from 2011 to 2024, the journal continues to emphasize the importance of thorough scientific inquiry, fostering advancements that drive both theoretical frameworks and practical applications in cell science.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.